U
CTIC

UBS’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

UBS’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3K Buy
143
+96
+204% +$2.5K ﹤0.01% 9923
2014
Q2 		$1K Sell
47
-2,471
-98% -$74.3K ﹤0.01% 10334
2014
Q1 		$86K Buy
2,518
+2,511
+35,871% +$85.8K ﹤0.01% 6191
2013
Q4 		$0 Sell
7
-2,728
-100% -$49.7K ﹤0.01% 11415
2013
Q3 		$44K Buy
2,735
+2,727
+34,088% +$31.6K ﹤0.01% 7050
2013
Q2 		$0 Buy
+8
New +$94 ﹤0.01% 10244

Other funds holding CTIC

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

UBS's CTIC Position: Q3 2014 in Review

UBS increased its CTI BioPharma Corp. (DE) Common Stock (CTIC) stake by 204% in Q3 2014, buying an estimated $2.5K and bringing the position to 143 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #9923.

UBS first reported a position in CTIC in Q2 2013 and has held it in 6 quarters since. The position peaked at $86K in Q1 2014. 85 funds tracked by Wall St. Rank hold CTIC as of Q3 2014.

  • UBS held 143 shares of CTI BioPharma Corp. (DE) Common Stock worth $3K as of Q3 2014.
  • UBS bought 96 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2014, an estimated $2.5K.
  • CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9923 holding.
  • UBS first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's CTI BioPharma Corp. (DE) Common Stock position peaked at $86K in Q1 2014.
  • 85 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.